Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody

Additional Information:
| Ramucirumab Biosimilar, Human VEGFR2 Monoclonal Antibody Recombinant Human IgG1 Monoclonal Antibody. Isotype: Human IgG1 kap|The monoclonal antibody ramucirumab biosimilar was produced in mammal cells. Specificity/Sensitivity: The monoclonal antibody ramucirumab biosimilar specifically binds to the human VEGFR2 (KDR). Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives. Endotoxin: Purity: >95% by SDS-|The research grade ramucirumab biosimilar protein is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is ramucirumab biosimilar research grade? Research grade Ramucirumab biosimilar uses the same protein sequences as the therapeutic antibody ramucirumab. Ramucirumab, a fully human IgG1 monoclonal antibody and a direct VEGFR2 antagonist, binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). These ligands are secreted by solid tumors to promote angiogenesis (formation of new blood vessels from pre-existing ones) and enhance tumor blood supply. Binding of ramucirumab to VEGFR2 leads to inhibition of VEGF-med tumor angiogenesis. Kinase insert domain receptor (KDR, a type IV receptor tyrosine kinase, CD309, cluster of different 309, Flk1, Fetal Liver Kinase 1) is the human gene encoding vascular endothel growth factor receptor 2 (VEGFR-2), which is a VEGF receptor. The Q472H germline KDR genetic var affects VEGFR-2 phosphorylation and has been found to assoc with microvessel density in NSCLC. Syd Labs also provides the following anti-VEGF or VEGFR antibody biosimilar protein: Bevacizumab Biosimilar, research grade (VEGF-A) Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli) Syd Labs also provides the following research grade antibody biosimilar proteins: Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR) Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR) Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu) Infliximab biosimilar, research grade (TNF alpha) Adalimumab biosimilar, research grade (TNF alpha) Rituximab biosimilar, research grade (CD20) Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF) Palivizumab Biosimilar, research grade (RSV) Omalizumab biosimilar, research grade (IgE) Eculizumab biosimilar, research grade (C5)